Genetic architecture of recent-onset dilated cardiomyopathy in Moravian region assessed by whole-exome sequencing and its clinical correlates
Language English Country Czech Republic Media print-electronic
Document type Journal Article
PubMed
30275597
DOI
10.5507/bp.2018.054
Knihovny.cz E-resources
- Keywords
- cardiac remodelling, dilated cardiomyopathy, familial cardiomyopathy, genetic architecture, next generation sequencing,
- MeSH
- Cardiomyopathy, Dilated epidemiology genetics physiopathology MeSH
- Adult MeSH
- Genetic Predisposition to Disease * MeSH
- Genetic Variation MeSH
- Middle Aged MeSH
- Humans MeSH
- Pilot Projects MeSH
- Prospective Studies MeSH
- Ventricular Remodeling genetics MeSH
- Retrospective Studies MeSH
- Exome Sequencing * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic epidemiology MeSH
AIMS: Recent-onset dilated cardiomyopathy (RODCM) is a disease of heterogeneous aetiology and clinical outcome. In this pilot study, we aimed to assess its genetic architecture and correlate genotype with left ventricular reverse remodelling (LVRR). PATIENTS AND METHODS: In this multi-centre prospective observational study, we enrolled 83 Moravian patients with RODCM and a history of symptoms of less than 6 months, for whole-exome sequencing (WES). All patients underwent 12-month clinical and echocardiographic follow-up. LVRR was defined as an absolute increase in left ventricular ejection fraction > 10% accompanied by a relative decrease of left ventricular end-diastolic diameter > 10% at 12 months. RESULTS: WES identified at least one disease-related variant in 45 patients (54%). LVRR occurred in 28 patients (34%), most often in carriers of isolated titin truncated variants, followed by individuals with a negative, or inconclusive WES and carriers of other disease-related variants (56% vs. 42% vs. 19%, P=0.041). CONCLUSION: A substantial proportion of RODCM cases have a monogenic or oligogenic genetic background. Carriers of non-titin disease-related variants are less likely to reach LVRR at 12- months than other individuals. Genetic testing could contribute to better prognosis prediction and individualized treatment of RODCM.
References provided by Crossref.org